Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 14;23(6):61.
doi: 10.1007/s11912-021-01052-8.

Immunotherapy in Cervical Cancer

Dennis Mauricio  1 , Burak Zeybek  1 , Joan Tymon-Rosario  1 , Justin Harold  1 , Alessandro D Santin  2
Affiliations
Review

Immunotherapy in Cervical Cancer

Dennis Mauricio et al. Curr Oncol Rep. .

Abstract

Purpose of review: This review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer.

Recent findings: There are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment. Multiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.

Keywords: Cervical cancer; Gynecologic malignancy; Immunotherapy; Targeted therapy; Therapeutic vaccines.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. - DOI - PubMed - PMC
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7–30. https://doi.org/10.3322/caac.21590 . - DOI - PubMed
    1. National Comprehensive Cancer Network, Clinical practice guidelines in oncology: cervical cancer, version 4. 2019. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf . March 29 2019.
    1. National Cancer Institute: cancer stat facts: cervix uteri cancer. https://seer.cancer.gov/statfacts/html/cervix.htm .
    1. Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22–30. https://doi.org/10.1016/j.ajog.2015.07.022 . - DOI - PubMed

MeSH terms

Substances